Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici

POSTED ON MARCH 23, 2021

Sanofi has concluded an agreement to divest an integrated portfolio of its anti-inflammatory drugs to Fidia Farmaceutici, a privately-held company headquartered in Italy. This transaction continues Sanofi’s ongoing strategic transformation by simplifying its portfolio and streamlining to enhance profitability.

“Established Products is an important growth driver for Sanofi, however, we are re-focusing our efforts as part of the company’s overall strategic transformation in order to pioneer new opportunities that will drive strong health outcomes for the millions of lives we touch,” commented Olivier Charmeil, Executive Vice President, General Medicines at Sanofi. “Upon completion of appropriate regulatory processes, today’s agreement with Fidia Farmaceutici will ensure patients will have continued access to these seven brands, while also allowing for us to further optimize our operating model through our Play to Win strategy.”

The agreement covers the registrations, trademarks, and related commercial rights of seven products, including four corticosteroids and one non-steroidal anti-inflammatory drug, across Europe and Emerging Markets. The products are already widely used to treat a broad range of conditions in various therapeutic areas.

“The acquisition confirms our will, despite the tough challenge created by Covid-19, to continue investing in core pharmaceutical business as part of our international growth, not only thanks to consolidation in the areas in which we are leaders, but also through more solid positioning as a result of entering different therapeutic areas,” explained Carlo Pizzocaro, President and Chief Executive Officer of Fidia Farmaceutici. “Furthermore, the acquisition represents an opportunity to strengthen managerial resources, under the framework of a sustainable annual average growth: once again, a development model that is characterized by the ability to face the challenges and seize the opportunities of tomorrow, in the long-term, although the world’s economies have been particularly battered.”

Commercial terms of the agreement will not be disclosed.

About Fidia Farmaceutici
Privately held, fully integrated Italian multinational company, with R&D, manufacturing, marketing and sales capabilities. The Company was founded in 1946 and is headquartered in Abano Terme (a short distance
Fidia’s overall objective is establishing its leadership, through an extensive product portfolio mainly based on hyaluronic acid (HA) in joint care, advanced wound care ophthalmology, aesthetic and autologous biological therapy, thereby providing patients and healthcare professionals with a variety of treatment options, such as pharmaceutical products, medical devices and food supplements. Over 55 years of R&D have placed Fidia at the forefront in the production of natural and functionalized HA, with different ranges of MW (1,100 patents). Manufacturing operations - located in Italy - are inspected and approved by major international health authorities, including the US and Korean FDA, the Brazilian ANVISA and G-MED Notified Body, and comply with the strictest international regulations and safety standards. Fidia extends its global reach through local partners in 100+ countries worldwide, as well as wholly-owned subsidiaries in USA, Germany, Austria, Spain, France, Russia, Czech Republic, Slovakia, Romania, Egypt and Middle East.

For more information about Fidia:  
www.fidiapharma.com
actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.